Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 生物股份 |
|---|---|
| Other Market Stock Code | 600201 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Cansinobio |
|---|---|
| Stock Code | 06185 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 研發、生產和商業化高質量、創新及經濟實惠的疫苗。公司正為12個疾病領域研發15種在研疫苗,涵蓋腦膜炎球菌疫苗、DTcP疫苗、肺炎球菌疫苗等,並已建成達國際標準的天津生產廠房。 |
| Listing Date | 2019-03-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國天津市經濟技術開發區西區南大街185號西區生物醫藥園四層401-420 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | cansinotech.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 22.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 200 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2019-03-18 to 2019-03-21 |
| Global Offering Shares | 57,248,600 shares |
| HK Public Offer Shares (Initial) | 5,725,200 shares (10.0%) |
| Public Offer Lots (Initial) | 28,626lots (Pool A14,313lots,Pool B14,313lots) |
| International Placing Shares (Initial) | 51,523,400 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 218,199,499 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 28.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,259,469,200 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 3.79B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣138.3百萬元 |
| Period-End Cash Balance | 人民幣57.4百萬元 |
| Listing Expenses | ~HK$ 107,300,000 |
| Listing Expenses / Funds Raised | ~8.52% |
| Total Pre-IPO Investment | 人民幣743百萬元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 0 | 0 | 1,132 |
| Other income and gains, net | 9,873 | 20,992 | 19,962 |
| Administrative expenses | -10,892 | -16,686 | -46,231 |
| Operating profit | -52,686 | -63,796 | -138,578 |
| Net finance costs | 2,835 | -654 | 297 |
| Profit before tax | -49,851 | -64,450 | -138,281 |
| Income tax expense | 0 | 0 | 0 |
| Profit for the year | -49,851 | -64,450 | -138,281 |
| Profit attributable to owners | -49,851 | -64,450 | -138,281 |
Balance Sheet
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Cash and cash equivalents | 52,548 | 18,247 | 57,381 |
| Inventories | 0 | 1,624 | 8,494 |
| Total current assets | 146,805 | 426,918 | 221,004 |
| Total assets | 326,173 | 866,364 | 795,875 |
| Total current liabilities | 27,356 | 112,927 | 106,685 |
| Total liabilities | 111,700 | 259,032 | 293,558 |
| Total equity | 214,473 | 607,332 | 502,317 |
| Equity attributable to owners | 214,473 | 607,332 | 502,317 |
| Interest-bearing borrowings | 69,329 | 108,333 | 150,000 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Net cash from operating activities | -34,383 | -56,301 | -123,638 |
| Net cash from investing activities | -173,543 | -461,490 | 117,625 |
| Net cash from financing activities | 150,815 | 484,372 | 45,055 |
| Net increase in cash | -57,111 | -33,419 | 39,042 |
| Purchase of PP&E | -126,080 | -164,469 | -149,423 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 34.7 |
|---|---|
| First Day Open | HK$ 30.5 |
| First Day Change | 57.73% |
| First Day Volume | 25930000.0 |
| First Day Turnover | 820373000.0 |
| Use of Proceeds | 1、約80%(或920.7百萬港元)將用于我們核心產品以及我們疫苗產品線中其他主要產品的研發及商業化;
2、約10%(或115.1百萬港元)將用于臨床前在研疫苗的持續研發;
3、約10%(或115.1百萬港元)將用于營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (5)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | LAV Amber Limited | 78,478,400 HKD | — | 6.23% | — | 6 months | 2019-09-28 |
| 2 | Worldwide Healthcare Trust PLC | 196,200,400 HKD | — | 15.58% | — | 6 months | 2019-09-28 |
| 3 | 津联卓睿投资有限公司 | 78,478,400 HKD | — | 6.23% | — | 6 months | 2019-09-28 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Xuefeng YU | — |
| Company Secretary | 崔進、趙明璟 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東為Yu博士、朱博士、Qiu博士及Mao博士(根據一致行動人協議),緊隨全球發售完成後各自持有本公司總股本約31.71%、35.37%、31.71%及31.71%;LAV持有約15.47%。 |
|---|




